FIRST AIRED: January 26, 2017

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



>> The drugs Actelion makes treat rare diseases. Pulmonary hypertension, for example, is thought to affect less than one in 20,000. But that's exactly what makes the Swiss firm attractive. High prices, high margins, that Johnson & Johnson has agreed to buy for $30 billion.>> Actelion is the darling of European biotech.
You don't get much better than Actelion. The drugs that they have created for hypertension, pulmonary hypertension are industry leaders. You know you're buying into the expertise.>> The deal values Actelion shares at $280, 23% more than Wednesday's close and more than 80% over where they were when takeover talks began In November.
But even so, the deal doesn't include Actelion's R&D unit, that's being spun off as a separate company led by the firm's founder. But Johnson and Johnson clearly feel it's money well spent. A look ahead, perhaps, to prices post Trump.>> You'd have to say that if the Trump presidency's for anything, its keeping intellectual property within the United States, and profiting from that.
So it'd be interesting to see whether we start to see pharmaceutical prices outside of the US rise as a result.>> Shares already have. Actelion stock jumping 20% on news of the sale.